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computed tomography showed that the size of the aneurysm was
reduced. The patient’s renal function recovered to preoperative
levels after a transient use of hemodialysis. The patient was dis-
charged from our hospital without blood-streaked sputum.
Discussion
The MK stent graft is a flexible, custom-made, curved stent graft.
It usually takes a week until we receive the stent graft after placing
an order. In this case the MK stent graft fit tightly to the 3-dimen-
sional curvy portion of the aorta and did not cause kinking or
endoleak at all. Although total replacement of the aortic arch
would be one of the best solutions for the aortic arch aneurysm,
this procedure is surgically stressful, especially for patients with
complications.5 Advantages of endovascular stent graft delivery
with extra-anatomic arch vessel bypass by SCP are relief from
cardiac arrest, relief from circulatory arrest, and relief from use of
an oxygenator. The preoperative creatinine clearance value of this
patient was 18 mL/min, and the postoperative renal function re-
covered to preoperative levels after transient use of dialysis. This
suggested that the level of surgical stress of this procedure was
acceptable for this patient. SCP alone requires lower levels of
heparinization than cardiopulmonary bypass because of the lack of
an oxygenator. It is a big advantage of this procedure to prevent
bleeding in a patient with such potential for massive lung bleeding.
To reduce the risk of brain complications, we closed the arch
vessels before the use of the side-biting clamp.
Endovascular delivery of the MK stent graft with extra-ana-
tomic arch vessel bypass by using SCP could be a useful and
minimally invasive therapeutic strategy for patients with aortic
arch aneurysms who are considered at high surgical risk.
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Does bridging to transplantation with a left ventricular assist device
adversely affect posttransplantation survival? A comparative analysis of
mechanical versus inotropic support
Jeffrey A. Morgan, MD, YooKyung Park, BS, Aftab R. Kherani, MD, Deon W. Vigilance, MD, Faisal H. Cheema, MD,
Mehmet C. Oz, MD, and Yoshifumi Naka, MD, PhD, New York, NY
Implantation of a left ventricular assist device (LVAD) as abridge to transplantation has become an acceptable interven-tion in patients with end-stage heart failure.1,2 Patientsbridged to transplantation with LVADs have demonstrated
improvements in blood pressure, hepatic function, renal function,
physical function, and quality of life.3,4 However, whether me-
chanical support adversely affects posttransplantation survival is
still controversial.5 Do patients bridged to transplantation with an
LVAD demonstrate decreased posttransplantation survival com-
pared with patients bridged with inotropic support? The aim of this
study was to answer this question.
Patients and Methods
We retrospectively reviewed our experience at Columbia Presby-
terian Medical Center with bridge-to-transplantation patients from
June 1996 through September 2002. During this time period, 266
patients in United Network for Organ Sharing status 1 were
successfully bridged to transplantation by either mechanical (n 
121, 45.7%) or inotropic (n 145, 54.5%) support. LVAD support
was provided by the HeartMate single-lead vented electric device
(Thoratec, Pleasanton, Calif). Posttransplantation survival at 1, 3,
and 5 years was evaluated in both groups.
Data were represented as frequency distributions and percent-
ages. Values of continuous variables were expressed as means 
SD. Continuous variables were compared by independent samples
t tests, whereas categorical variables were compared by 2 tests.
Kaplan-Meier analysis was used to calculate survival. Actuarial
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survival at 1, 3, and 5 years after transplantation was calculated by
constructing life tables. Significant risk factors for mortality were
identified by multivariate Cox proportional hazard models. All
data were analyzed with SPSS 11.5 software (SPSS Inc, Chicago,
Ill).
Results
Demographics. Clinical demographics of patients in both
groups are outlined in Table 1. Patients supported with LVADs
were significantly younger than patients supported with inotropic
therapy (48.7 14.0 years vs 52.6 13.6 years, P .023). There
were significantly more male patients in the LVAD group (85.1%
vs 73.1%, P  .017). There was no significant difference in cause
of heart failure between the groups.
Posttransplantation survival. Both groups demonstrated sim-
ilar posttransplantation survival (P  .649, Figure 1). Actuarial
survival at 1, 3, and 5 years was 92.4%, 83.6%, and 74.4%,
respectively, for the LVAD group, and 90.8%, 84.0%, and 73.2%,
respectively, for the medical therapy group.
Risk factors for mortality. On the basis of univariate analy-
sis, pretransplantation LVAD support was not a statistically
significant risk factor for posttransplantation mortality (P 
.928). Sex was the only significant predictor of survival, with
male patients demonstrating improved survival over that of
female patients (P  .001). Other variables evaluated included
age (P  .344), race (P  .518 for white patients, P  .312 for
African American patients, and P  .733 for “other” patients),
and cause of heart failure (P  .807 for coronary artery disease,
P  .790 for idiopathic cardiomyopathy, and P  .965 for
“other”).
On the basis of multivariate analysis with Cox propor-
tional hazard models, female sex was the only variable
demonstrated to be a statistically significant risk factor for
decreased posttransplantation survival (odds ratio, 3.518;
95% confidence interval, 1.813-6.827; SE, 0.338; P 
.001).
Discussion
In our study we demonstrated that patients bridged to trans-
plantation with mechanical support had similar posttransplan-
tation survival compared with that of United Network for Organ
Sharing status 1 patients bridged with inotropic drugs. The
HeartMate device, the first LVAD to gain US Food and Drug
Administration approval for use as a bridge to transplantation,
is the preferred device at our institution. It accommodates
mobility, allowing patients to be discharged from the hospital
and resulting in improved quality of life. It also obviates the
need for anticoagulation.4
Limitations of this comparative study include that it was not
a randomized study of LVAD versus inotropic therapy. LVADs
were generally reserved for patients who had signs and symp-
toms of severe heart failure refractory to medical therapy.
Therefore, patients supported with LVADs tended to manifest
more severe clinical heart failure with a greater degree of
instability than patients who were bridged to transplantation
with inotropic drugs.
In conclusion, although the paradigm for assist devices might
shift to a bridge to recovery or destination therapy, the role of an
LVAD as a bridge to transplantation for patients with end-stage
heart failure will remain an important one. At our institution, over
the past 6 years, 71.2% (n  121) of the 170 patients who
underwent implantation of single-lead vented electric HeartMate
devices as a bridge to transplantation were successfully bridged.
LVADs permitted stabilization and optimization of patients with
severe congestive heart failure without adversely affecting post-
transplantation survival.3 A prospective randomized trial evaluat-
ing LVADs versus inotropic support for bridge-to-transplantation
patients might be warranted to evaluate this issue more exten-
sively.
TABLE 1. Baseline clinical characteristics of patients
Variable LVAD
Medical
therapy P value
Mean age (y) 48.7 14.0* 52.6 13.6 .023†
Sex
Male 103 (85.1)‡ 106 (73.1) .017
Female 18 (14.9) 39 (26.9)
Race
White 88 (72.7) 102 (70.3) .668
African American 24 (19.8) 24 (16.6) .488
Other 9 (7.4) 19 (13.1) .134
Cause of heart failure
CAD 54 (44.6) 58 (40.0) .425
ICM 61 (50.4) 76 (52.4) .774
Other 6 (5.0) 11 (7.6) .314
CAD, Coronary artery disease; ICM, idiopathic cardiomyopathy.
*Mean  SD.
†P value from independent samples t tests.
‡Absolute number (percentage).
Figure 1. Actuarial posttransplantation survival for patients sup-
ported with LVADs versus medical therapy.
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Fifteen-month circulatory support for sustained ventricular fibrillation by
left ventricular assist device
Motonobu Nishimura, MD, Masanori Ogiwara, MD, Masayuki Ishikawa, MD, Syogo Yatsu, MD, Ayumu Masuoka, MD,
Nobuyuki Okamura, MD, Kazuhito Imanaka, MD, Masaaki Kato, MD, Haruhiko Asano, MD, and Shunei Kyo, MD,
Saitama, Japan
Patients with end-stage heart failure who receive supportfrom a left ventricular assist system (LVAS) have beenshown to tolerate malignant ventricular arrhythmia fairlywell.1,2 The duration of malignant arrhythmia in the
previous reports was at most a little more than 10 days. This report
describes a patient who has been in sustained ventricular fibrilla-
tion (VF) for more than 1 year and has been supported by an
LVAS without showing any symptoms.
Clinical Summary
A 24-year-old woman, who demonstrated dilated cardiomyopathy,
was first referred to us for heart failure and ventricular arrhythmia
5 years ago. At that time, she received the maximum medication
and did well. She remained well until the age of 23 years, when she
returned with profound heart failure and ventricular tachyarrhyth-
mia resistant to medical therapy. Catecholamine was administered,
and workup for cardiac transplantation was started. She experi-
enced VF and was resuscitated using the percutaneous extracor-
poreal membrane oxygenator system (Emersave, Terumo, Tokyo,
Japan). She was immediately brought to the operating room, where
she underwent emergency placement of the Toyobo-NCVC LVAS
(Toyobo, Osaka, Japan) with left ventricular drainage. Her post-
operative course was essentially uneventful, but her ventricular
arrhythmia continued despite aggressive antiarrhythmia medica-
tion. Three months after placement of the LVAS, she experienced
VF again, which was resistant to external cardioversion (Figures
1A and 1B). Although her heart had been fibrillated, her LVAS
flow was almost unchanged (3-4 L/min), and she showed no
symptoms. Despite all the attempts to restore her original rhythm,
she remained in VF. After several days, we stopped the attempts
because she had been well with no symptoms, and further attempts
may have caused embolism as the result of intracardiac thrombus.
Since then, her heart has been in sustained VF for 15 months, but
she has been ambulated, like other patients supported by an LVAS,
while awaiting heart transplantation (Figure 2). Although her right
ventricle is not working, she has not demonstrated peripheral
edema, pleural effusion, or ascites. Her pulmonary vascular resis-
tance before LVAS placement was 2.44 Wood units. Her central
venous pressure 3 months after demonstrating VF was approxi-
mately 10 mm Hg. Cardiac catheterization was not performed after
sustained VF because of possible thrombus in her fibrillated heart.
Discussion
Sustained VF is not a lethal arrhythmia for patients supported by
an LVAS. In a report by Oz and associates,1 an LVAS was
successful in supporting 9 patients who continued to experience
malignant ventricular arrhythmia during device support. The ar-
rhythmias lasted from 10 minutes to 12 days. The patients reported
weakness, but none reported syncope. Fasseas and coworkers3
reported the successful use of an LVAS for the management of
refractory ventricular arrhythmia. Nonetheless, early electrical car-
dioversion is indicated in patients demonstrating sustained VF
with LVAS support because usually there is more than a 1 L/min
decrease in device flow at the onset of VF.1
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